Thermodynamic, spectral and antimicrobial activity of inclusion complexes of acridone and its oxime with β-cyclodextrin

الموضوعات : Journal of the Iranian Chemical Research

Swapna Sankar Nayak ¹ , Sunakar Panda ²

1 - PG Department of Chemistry, Berhampur University, Bhanja Vihar 760007, India
2 - S.B.R. Govt. Women’s (Auto) College, Berhampur 760001, India

تاريخ الإرسال : 17 الأربعاء , جمادى الثانية, 1430 تاريخ التأكيد : 21 الإثنين , ذو القعدة, 1430 تاريخ الإصدار : 14 الخميس , محرم, 1431

الکلمات المفتاحية: Acridone, Inclusion complex, β-cyclodextrin, Thermodynamic stability, Antimicrobial study,

ملخص المقالة :

One of the methods to enhance bio-accessibility of drugs like Acridone and its oxime is toform inclusion complexes with β-cyclodextrin. The formation of such complexes has beenconfirmed by changes in spectral characteristics and melting point data. The aqueous phasesolubility studies reveal 1:1 stoichiometry between the compound and, β-cyclodextrin. The studyof thermodynamic parameters like ΔG, ΔH, ΔS indicates the inclusion complex formation to beexothermic and spontaneous. The study of antimicrobial activity of these compounds indicatesthat the microbes like E. coli and P. aeruginosa are susceptible and the susceptibility increasessignificantly after formation of inclusion complex.

المصادر:

[1] P. Belmont, I. Dorange, Expert opinion on Therapeutic Patents 18 (2008) 1211-1215.
[2] P. Belmont, J. Bosson , T. Godet, M. Tiano, Curr. Med. Chem. Anticancer Agents 7 (2007) 139-144.
[3] A. Verloop, W. Hoogentraten, J. Tipker, Drug Design 7 (1976) 165-168.
[4] B. Pose-Vilarnovo, I. Perdomo-Lopez, M. Echezarreta-Lopez, Eur. J. Pharm. Sci. 13 (2001) 325-334.
[5] V.G. Belikov, E.V. Kompantseva, Khim-Farm Zh. 24 (1990) 19-27.
[6] H. Yano, F. Hirayama, H.Arima , J. Pharm. Sci. 90 (2001) 493-496.
[7] X. Jane, M. Kelly, Antimicrob. Agents Chemother. 51 (2007) 4133-4137.
S.S. Nayak & S. Panda / J. Iran. Chem. Res. 2 (2009) 257-265
265
[8] T. Higuchi, K.A. Connors Adv. Anal. Chem. Instrum. 4 (1965) 117-211.
[90] C.F.H. Allen, G.H.W. Mckee, Organic Syntheses Coll. 2 (1943) 15-16.
[10] N. Shufang, F. Xiawen, P. Ying, Y. Xingang, W. Chow, P. Weisan, P. Arch, Pharm. Res. 30 (2007)
991-993
[11] S. Panda, J.K. Tripathy, J. Env. Res. Dev. 3 (2008) 45-49.
[12] M.J. Pelzar, E.C.S. Chan, N.R. Kreig, Microbiology, Wiley Interscience, New York, 1983.
[13] K.J. Ryan, C.G. Ray, Sherris Medical Microbiology, McGraw Hill ,London, 2004.
[14] K.G. Mohamed, C.A. Moji , Pharm. Dev. Tech. 6 (2001) 315-318.
[15] O. Chen, D. Guowang, Chem. J. Internet. 6 (2004) 37-39.
[16] A. Modi, P. Tayade, Indian J. Pharm. Sci. 69 (2007) 274-278.
[17] H.A. Benesi, J.H. Hilderbrand, J. Am. Chem. Soc.71 (1999) 2703-2704.
[18] Z. Szetli, Controlled Drug Bioavailability, Wiley Interscience, New York, 1985.
[29] S. Tommasini, D. Raneri, R. Ficarra, M.L. Calabro, R. Stancanelli, J. Pharm. Biomed. Anal. 35
(2004) 379-382.
[20] R.A. Rajewski, V.J. Stella, J. Pharm. Sci. 85 (1996) 1142-1145.
[21] Y.L. Loukas, V. Vraka, G. Gregoridias, J. Pharm. Biomed. Anal. 16 (1997) 263-271.
[22] T. Stalin, P.V. Rani, B. Shanthi, A. Sekar, N. Rajendiran, Indian J. Chem. Sect A 45 (2006) 1113-
1120.
[23] A.V. Astakhova, N.B. Demina, Pharm. Chem. J. 38 (2004) 105-108.